Search Options Stock News and Analysis from Schaeffer's

https://www.schaeffersresearch.com/content/news/2024/12/11/biotech-roundup-3-stocks-to-watch

12/11/2024 3:35 PM

Most recently in the ever-growing biotech industry, investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and D...

Drug Sales Surge Drives Regeneron Pharmaceuticals to Q2 Beat

https://www.schaeffersresearch.com/content/news/2023/08/03/drug-sales-surge-drives-regeneron-pharmaceuticals-to-q2-beat

8/3/2023 10:40 AM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported second-quarter revenue of $10.24 per share on revenue of $3.16 billion today, blowing past analysts' expectations. The company attributed the resu...

Biotech Stock Sitting Out Today's Rally

https://www.schaeffersresearch.com/content/news/2022/10/17/biotech-stock-sitting-out-today%27s-rally

10/17/2022 10:27 AM

While the rest of the market is making moves higher today, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is static, last seen off 0.1% at $735.31. Evercore downgraded REGN to "in-line" from "outperform...

Top- and Bottom-Line Beat Gives Regeneron Stock a Boost

https://www.schaeffersresearch.com/content/news/2022/02/04/top-and-bottom-line-beat-gives-regeneron-stock-a-boost

2/4/2022 10:26 AM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for its fourth quarter, which included revenues nearly...

Biotech Stock Starts Rocky Month with Covid-19 Headwinds

https://www.schaeffersresearch.com/content/news/2021/12/01/biotech-stock-starts-rocky-month-with-covid-19-headwinds

12/1/2021 11:28 AM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been in the spotlight this week, after the company's CEO Leonard Schleifer noted its Covid-19 antibody cocktail may be less effective against the omicro...

PEOPLE ALSO SEARCH FOR